IP Library Granted Patent US 8,518,397
Granted Patent B2
US 8,518,397 · App. 12/855,203 · Granted Aug 27, 2013

Notch induced natural killer cell generation and therapeutic uses

Inventor: Rose C. Beck (Cleveland Heights, OH)
Assignee: Case Western Reserve University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,518,397
App. No.
12/855,203
Granted
Aug 27, 2013
Kind
B2
Abstract

A method of preparing differentiated NK cells by ex vivo expansion includes the steps of; (1) isolating a plurality of CD34 + hematopoietic cells; (2) culturing the cells in a medium, wherein the medium includes an effective amount of a notch ligand and one or more cytokines selected from the group consisting of IL-7, IL-15, SCF, Flt-3, IL-3 and IL-6; and (3) maintaining the cells in culture for a duration of time sufficient to produce NK cells.

Claims (13)

1. A method of preparing differentiated NK cells by ex vivo expansion comprising:

isolating a plurality of CD 34+ hematopoietic cells;

culturing the cells in a medium free of stromal cells, wherein the medium includes an effective amount of a notch ligand and IL-7, IL-15, SCF, Flt-3 and IL-3, the notch ligand being immobilized on a solid substrate that facilitates interaction of the CD34+ cells and the notch ligand, wherein the solid substrate is suspended in the medium; and

maintaining the cells in culture for a duration of time sufficient to produce NK cells.

2. The method of claim 1 , the notch ligand comprising delta4 notch ligand.

3. The method of claim 1 , wherein the NK cells lack MHC class I inhibitory signals.

4. The method of claim 1 , wherein the NK cells do not express an inhibitory receptor surface protein selected from KIR and NKG2A.

5. The method of claim 1 , the solid substrate comprising a plurality of protein A beads.

6. The method according to claim 5 , wherein the protein A beads are used at a concentration of at least 0.01 μg/ml to 100 μg/ml.

7. The method of claim 1 wherein the hematopoietic cells are derived from umbilical cord blood.

8. The method of claim 1 , the medium further comprising IL-6.

9. The method of claim 1 , the predetermined time period comprising between about 2 weeks and about 6 weeks.

10. The method of claim 1 , wherein the NK cells have at least the following characteristics: CD56 bright , CD16 − , CD117 + , KIR − , CD94 low , CD11b−.

Continuity (2)
Provisional Application 61233968 · Aug 14, 2009
Related Publication 20110044962A1 · Feb 24, 2011